Precision Optics Reports Third Quarter Fiscal Year 2021 Financial Results

May 13, 2021

GARDNER, Mass., May 13, 2021 /PRNewswire/ — Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its third quarter fiscal year ended March 31, 2021.

Third quarter fiscal 2021 highlights:

Revenue for the quarter ended March 31, 2021 was $2.46 million compared to $2.37 million in the same quarter of the previous fiscal year.
Gross margins for the quarter ended March 31, 2021 were 33% compared to 34% in the same quarter of the previous fiscal year; and compared to 31% for the quarter ended December 31, 2020.
Net Income of $552,280 during the quarter included $809,000 of Other Income due to the forgiveness of the SBA PPP Loan as well as $86,000 of stock-based compensation. This compared to a loss of $466,000, including $76,000 of stock-based compensation in the same quarter of the previous fiscal year.
The Company’s cash position remains strong with an ending balance for the third quarter of $782,000.

Precision Optics’ CEO, Joseph Forkey, commented, “The market opportunity for micro-optic and 3D-enabled devices and components in the medical and defense industries continues to be robust. Large, established industry players, and well-funded startup companies are looking for enabling technology partners, such as Precision Optics, that can make next generation products a reality. Over the past couple of years, we have made significant progress expanding the number of jointly developed projects in our engineering pipeline. We expect many of these to move into production in the coming year to help drive growth.”

Dr. Forkey continued, “While our ongoing production levels continue to be depressed due to the pandemic, the increase in engineering pipeline activity has helped to cushion the impact on overall revenues. Our production revenue of $1.9 million during the quarter was flat compared to the most recent quarter and was down about $250,000 from the third quarter a year ago. Engineering revenue of $550,000 was down sequentially, but was up year-over-year, and is expected to increase again in future quarters. Due to revenue recognition timing, reported revenue growth quarter-to-quarter may not reflect the full underlying growth trend of the business. Further, we have efficiently managed the business with year-to-date improvements in adjusted EBITDA of over $500,000 compared to the same period a year ago. With a burgeoning pipeline, near-term projects expected to move from the pipeline to production, and the resumption of normalized production levels for products impacted by the pandemic, we believe we are well positioned heading into fiscal 2022.”

The following table summarizes the third quarter (unaudited) results for the periods ended March 31, 2021 and 2020:

		Three Months
		Ended Mar 31,
		2021	2020
Revenues		$ 2,458,290	$ 2,374,584

Gross Profit		818,024	817,019

Stock Compensation Expenses		74,794	64,334
Other		999,248	1,218,132
Total Operating Expenses		1,074,042	1,282,466

Operating Income (Loss)		(256,018)	(465,447)

Net Income (Loss)		552,278	(466,130)

Income (Loss) per Share
	Basic	$ 0.04	$ (0.04)
	Fully Diluted	$ 0.04	$ (0.04)

Weighted Average Common Shares Outstanding
	Basic	13,243,595	12,982,494
	Fully Diluted	14,068,459	12,982,494

Conference Call Details

The Company has scheduled a conference call to discuss the third quarter 2021 financial results for Thursday, May 13, 2021 at 5:00pm ET.

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or

(412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available at https://www.webcaster4.com/Webcast/Page/2109/40924.

Replay: A teleconference replay of the call will be available until May 20, 2021 at (877) 344-7529 or (412) 317-0088, confirmation # 10155310. A webcast replay will be available at https://www.webcaster4.com/Webcast/Page/2109/40924.

About Precision Optics Corporation

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

About Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Company Contact:

PRECISION OPTICS CORPORATION

22 East Broadway

Gardner, Massachusetts 01440-3338

Telephone: 978-630-1800

Investor Contact:

LYTHAM PARTNERS, LLC

Robert Blum

Phoenix | New York

Telephone: 602-889-9700

peye@lythampartners.com

Following are the Company’s Consolidated Balance Sheets at March 31, 2021 and June 30, 2020, and Statements of Operations, for the three and nine month periods ended March 31, 2021 and 2020:

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	March 31, 2021		June 30, 2020
ASSETS
Current Assets:
Cash and cash equivalents	$	781,845	$	1,134,697
Accounts receivable (net of allowance for doubtful accounts of $250,633 at March 31, 2021 and $248,450 at June 30, 2020)		1,533,781		1,481,437
Inventories		1,949,281		2,197,244
Prepaid expenses		132,156		133,707
Total current assets		4,397,063		4,947,085

Fixed Assets:
Machinery and equipment		3,084,691		2,907,533
Leasehold improvements		765,780		731,801
Furniture and fixtures		178,640		178,640
		4,029,111		3,817,974
Less—Accumulated depreciation and amortization		3,419,203		3,314,824
Net fixed assets		609,908		503,150

Operating lease right-to-use asset		75,804		118,403
Patents, net		135,536		95,229
Goodwill		687,664		687,664

TOTAL ASSETS	$	5,905,975	$	6,351,531

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current portion of capital lease obligation	$	37,779	$	51,761
Current portion of acquisition earn out liability		166,667		166,667
Note payable to bank		–		808,962
Accounts payable		1,024,611		1,066,005
Customer advances		232,884		417,059
Accrued compensation and other		585,463		581,770
Current portion of operating lease liability		60,131		57,156
Total current liabilities		2,107,535		3,149,380

Capital lease obligation, net of current portion		162,200		35,810
Acquisition earn out liability		166,666		333,333
Operating lease liability, net of current portion		15,673		61,247

Stockholders’ Equity:
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 13,263,789 shares at March 31, 2021 and 13,191,789 June 30, 2020		132,638		131,918
Additional paid-in capital		50,044,789		49,702,986
Accumulated deficit		(46,723,526)		(47,063,143)
Total stockholders’ equity		3,453,901		2,771,761

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	5,905,975	$	6,351,531

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED
MARCH 31, 2021 AND 2020
(UNAUDITED)

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Revenues	$	2,458,290	$	2,374,584	$	8,001,641	$	7,686,330

Cost of Goods Sold		1,640,266		1,557,565		5,353,999		4,977,255
Gross Profit		818,024		817,019		2,647,642		2,709,075

Research and Development Expenses, net		146,063		319,875		443,609		700,605
Selling, General and Administrative Expenses		927,979		962,591		2,671,176		3,111,397
Total Operating Expenses		1,074,042		1,282,466		3,114,785		3,812,002

Operating Loss		(256,018)		(465,447)		(467,143)		(1,102,927)

Other Income (Expense)
Interest Expense		(666)		(683)		(2,202)		(138)
Gain on Forgiveness of Bank Note		808,962		–		808,962		–

Net Income (Loss)	$	552,278	$	(466,130)	$	339,617	$	(1,103,065)

Income (Loss) Per Share:
Basic	$	0.04	$	(0.04)	$	0.03	$	(0.09)
Fully Diluted	$	0.04	$	(0.04)	$	0.02	$	(0.09)

Weighted Average Common Shares Outstanding:
Basic		13,243,595		12,982,494		13,208,805		12,898,004
Fully Diluted		14,068,459		12,982,494		13,841,700		12,898,004